Indefinite Delivery Contract SPE2DX17D9785

The federal contract IDV awarded to DMS Pharmaceutical Group Inc. is a single-award Indefinite Delivery Contract (IDC) with the Defense Logistics Agency (DLA) under the SPE2DB program, valued at $499,999,999 and valid through November 2026. This IDC enables the DLA to issue firm fixed-price delivery orders for a comprehensive range of pharmaceutical items to support the medical supply needs of military health facilities worldwide. The contract covers an extensive portfolio of pharmaceutical products, including branded and generic prescription drugs, over-the-counter medications, biologics, and medical consumables across various product categories such as injections, tablets, creams, auto-injectors, and specialty medications.

As a woman-owned small business, DMS Pharmaceutical Group has demonstrated its capability to provide a diverse array of pharmaceutical products to the DLA through its previous contract awards. The company's contract awards include delivery orders for specialized medications such as Xolair, Trikafta, Keytruda, Botox, Nucala, and various other prescription drugs and medical supplies. These contracts are predominantly awarded as firm fixed-price delivery orders and cover a wide range of medical needs, including oncology treatments, contraceptives, auto-injectors, and specialized pharmaceutical products. This IDC positions DMS Pharmaceutical Group as a crucial supplier in the federal pharmaceutical supply chain, providing direct distribution of prescription drugs and pharmacy services to Department of Defense healthcare sites.